Cardiovascular disease is by far the most common cause of death worldwide, and myocardial infarction is the most common acute ...

Patients suffering from myocardial infarction who receive early add-on lipid-lowering medication have a significantly better ...

Patients suffering from myocardial infarction who receive early add-on lipid-lowering medication have a significantly better prognosis than those who ...

Early ezetimibe initiation after myocardial infarction significantly lowers cardiovascular events compared to delayed or no combination lipid-lowering therapy.

Cardiovascular disease is by far the most common cause of death worldwide, and myocardial infarction is the most common acute event.

Giving patients a combination of drugs earlier in their treatment could prevent thousands of heart attacks, according to a ...

The new clinical guide reveals gender-specific cardiovascular risks and prevention strategies for women across all life ...

Analysis suggests that treating heart attack patients earlier with a combination of statins and the cholesterol-lowering drug ezetimibe could prevent thousands of new heart attacks over a decade.

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Adding ezetimibe (Zetia) therapy to statins early after a heart attack improved outcomes, Swedish national records suggested.

The direct oral anticoagulant is an effective alternative to warfarin that offers predictable dosing without the need for ...

Treating patients earlier with a combination of statins and the cholesterol-lowering drug ezetimibe could prevent thousands of new heart attacks, strokes, and death over a decade, according to ...